New combo therapy for lung cancer shows promise in early trial
NCT ID NCT01167530
First seen Apr 09, 2026 · Last updated Apr 29, 2026 · Updated 5 times
Summary
This early-phase study tested a drug called RAD001 (everolimus) combined with radiation therapy in 26 people with advanced non-small cell lung cancer that could not be removed by surgery. The goal was to find safe doses and check for side effects. Participants took RAD001 weekly or daily before, during, and after radiation, followed by chemotherapy. The study focused on safety and tumor response, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Gustave Roussy
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.